| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H69N11O3 |
| Molecular Weight | 788.0799 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=C(C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCC2=CC=CC=C2)C3=C(N1)C(=CC(=C3)C(C)(C)C)C(C)(C)C
InChI
InChIKey=ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1
| Molecular Formula | C43H69N11O3 |
| Molecular Weight | 788.0799 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
LTX109 is a synthetic antimicrobial agent and is a potent fungicide that disturbs plasma membrane integrity in a sphingolipid dependent manner. LTX109 was in clinical phase II trials for topical treatment of infections of multiresistant bacterial strains. However, the further development of this drug apparently has been discontinued.
Originator
Approval Year
PubMed
Sample Use Guides
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA). Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2% LTX-109/placebo and finally group 3: 5% LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
Route of Administration:
Topical
